Skip to main content
Premium Trial:

Request an Annual Quote

Affitech Licenses Phage Display Tech to Dyax

NEW YORK, Dec. 21 (GenomeWeb News) - Oslo-based Affitech announced recently that it has licensed its phage display technology to Dyax, of Cambridge, Mass.


Dyax is the first licensee of Affitech's core patent portfolio, which covers phagemid display of antibodies and antibody fragments, Affitech said. Specifically, the worldwide patent covers the use of full-length pIII phage protein as a scaffold in a phagemid vector.


Affitech obtained the exclusive worldwide rights to the patent from the DKFZ (German Cancer Research Center) in Heidelberg, Germany.


Financial terms of the deal were not disclosed.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.